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Purpose: Currently >50% of high-risk neuroblastoma (NB) patients, despite intensive therapy
and initial partial or complete response, develop recurrent NB due to the persistence of minimal
residual disease (MRD) that is resistant to conventional antitumor drugs. Indeed, their low
therapeutic index prevents drug-dose escalation and protracted administration schedules, as
would be required for MRD treatment. Thus, more effective and less toxic therapies are urgently
needed for the management of MRD. To address this aim, we evaluated a new combination of
fenretinide and lenalidomide, both endowed with antitumor activity and low-toxicity profiles.
New nanomicelles were prepared as carriers for this combination tomaximize bioavailability and
accumulation at the tumor site because of the enhanced permeability and retention (EPR) effect.
Experimental design: New nanomicelles containing the fenretinide–lenalidomide combi-
nation (FLnMs) were prepared by a one-step method, providing high drug encapsulation and
micelle dimensions suitable for tumor accumulation. Their administration to mice bearing
human NB xenografts allowed us to evaluate their efficacy in comparison with the nanomi-
celles containing fenretinide alone (FnMs).
Results: Treatment by FLnMs significantly decreased the tumor growth of NB xenografts.
FLnMs were more active than FnMs despite comparable fenretinide concentrations in
tumors, and lenalidomide alone did not show cytotoxic activity in vitro against NB cells.
The tumor mass at the end of treatment with FLnMs was predominantly necrotic, with
a decreased Ki-67 proliferation index.
Conclusion: FLnMs provided superior antitumor efficacy in NB xenografts compared to
FnMs. The enhanced efficacy of the combination was likely due to the antiangiogenic effect
of lenalidomide added to the cytotoxic effect of fenretinide. This new nanomicellar combi-
nation is characterized by a low-toxicity profile and offers a novel therapeutic option for the
treatment of high-risk tumors where the persistence of MRD requires repeated administra-
tions of therapeutic agents over long periods of time to avoid recurrent disease.
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Introduction
Most therapeutic protocols for childhood cancers use cytotoxic agents that have a low
therapeutic index and result in significant short- and long-term toxicities. This prevents
further drug dose-escalation and limits the long-term treatment that is necessary for the
complete eradication of the malignant disease. The persistence of drug-resistant MRD
after cytotoxic chemotherapy is a frequent cause of relapse and treatment failure.1 In
high-risk neuroblastoma (NB), despite intensive therapy, more than 50% of patients
develop the recurrent disease due to the persistence of MRD that is unresponsive to
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conventional antitumor drugs.2 Therefore, new antitumor
treatments with low toxicity are urgently needed for high-
risk cancers such as NB. Many approaches are currently
being developed, including immunotherapy, gene therapy,
synergistic combinations and repurposing therapy.3 Another
approach is the enhanced drug delivery to solid tumors using
nanoparticles as carriers of active agents. Indeed, nanoparti-
cles selectively accumulate in solid tumors based on their size,
which allows extravasation through the leaky tumor vascula-
ture that characterizes rapidly growing tumors. The selective
accumulation increases the drug concentration in the tumor
microenvironment, thus improving its pharmacological effi-
cacy, while at the same time reducing the toxicity associated
with conventionally administered antitumor drugs.
The use of nanoparticles as carriers for alternative, anti-
tumor bioactive molecules (AABMs), is an emerging trend
in bio-nanomedicine aimed at administering tolerable com-
binations of antitumor agents for long periods of time
(months or years) until complete tumor eradication is
achieved. AABMs may be of natural origin (e.g., berberine,
curcumin, resveratrol, etc.) or vitamin analogues, such as
fenretinide (N-4-hydroxyphenyl-retinamide) or 13-cis-
retinoic acid.4 They are characterized by high tolerability,
and their antitumor effect mechanisms do not induce multi-
drug resistance. However, their hydrophobic character
strongly limits their bioavailability, and their low pharma-
cological potency only provides antitumor activity at high
concentrations that are difficult to achieve in vivo using
conventional formulations. We hypothesized that the use
of nanoparticles as carriers for these molecules would
increase their concentrations at the tumor site to levels
sufficient to have significant antitumor activity. Moreover,
the combination of AABMs with antiangiogenic drugs
might further improve their antitumor effect.
In this study, we used the AABM fenretinide in com-
bination with the antiangiogenic drug lenalidomide in
novel nanomicelles designed to provide high encapsulation
efficiency and drug loading capacity. We evaluated their
antitumor activity in an NB xenograft model.
Fenretinide is a semi-synthetic retinoid characterized by
high cytotoxic efficacy against a wide range of cancer cells
in vitro and previously investigated as a potential anticancer
and chemopreventive drug.5–13 Among the AABMs, fenre-
tinide has a superior pharmacological profile due to its ability
to induce cytotoxicity by multiple mechanisms14–18 and to
target cancer stem cell-associated molecular targets.19–22
Previous clinical Phase I–III evaluations of fenretinide
showed minimal systemic toxicity and good tolerability.9,23,24
However, clinical trials aimed at evaluating the activity of
fenretinide in cancer patients yielded disappointing results,
likely due to the low bioavailability of the initial oral capsule
formulation.5,10,23–25
Many attempts have been subsequently made to increase
fenretinide bioavailability, including drug incorporation in
a lipid solid matrix or in a lipid emulsion. These approaches
provided improved performance compared to the initial cap-
sule formulation. However, they still faced problems prob-
ably related to the strong drug-lipid association that limited
drug release, requiring high drug doses to achieve therapeutic
plasma drug concentrations.26–29
The recent approach of fenretinide nanoencapsulation in
amphiphilic macromolecules, polymers or phospholipids,
provided high levels of aqueous drug solubilization, bioavail-
ability and absorption at the tumor site.30–38 Preclinical stu-
dies on nanoformulations of fenretinide-cyclodextrin
complex37 and fenretinide-phospholipid salts38 indicated
high antitumour activity in cancer stem cells of various
origins in vitro, and in tumour xenografts derived from
cancer stem cells of lung cancer, colon cancer and melanoma
origin. Moreover, higher drug concentrations in blood and
tumours were obtained in the absence of toxicity.
Therefore, fenretinide nanoencapsulation in combination
with other drugs that have antitumor activity and low toxicity
may represent a further step towards the realization of new
therapeutic systems able to elicit effective therapeutic
responses in vivo, avoiding the need of conventional anti-
tumor drugs and their related short- and long-term toxicities.
Lenalidomide was selected to combine with fenretinide
because of its antiangiogenic properties and its acceptable
toxicity profile that has made it the standard drug used for
long-term treatment of multiple myeloma and other
cancers.39–43 The anti-angiogenic effect of lenalidomide has
not been fully evaluated in NB so far. However, lenalidomide
was reported to overcome the suppression of natural killer
cells in NB microenvironment, by activation of T cells to
secrete IL-2.44 Therefore, this drug might be particularly
interesting in NB tumors, which are characterized by high
vascularization45 and immune suppressive activity as well as
in other highly vascularized, tumor types.
Materials and Methods
Chemicals
Fenretinide (N-4-hydroxyphenyl-retinamide, 4-HPR) was
purchased from Olon Spa (Milan Italy), Lenalidomide
from AstaTech Inc (PA, USA) Soy L-α-phosphatidylcholine,
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glyceryl tributyrate, hydroxypropyl-beta-cyclodextrin (Mw
1460) and KOH from Sigma-Aldrich. Ethanol absolute anhy-
drous was purchased from Carlo Erba Reagents.
Nanomicelles Preparation
Soy phosphatidylcholine (4 mmoles), glyceryl tributyrate (2
mmoles) and KOH 10 N (4 mmoles) were mixed with
hydroxypropyl-beta-cyclodextrin (0.8 mmoles) to obtain
a semisolid phase. Fenretinide (1 mmole) was dissolved in
ethanol (300 µL) and KOH 10 N (1 mmole) and was sub-
sequently added to the mixture. Homogenization was car-
ried out in a mortar grinder (RM 200 Retsch Verder Italy)
for 30 mins at 100 min−1 rate. Afterwards, lenalidomide
(0.5 mmoles) was added, and mixing was continued for
another 30 mins until homogeneity. The resultant semisolid
phase was dissolved in water (50 mg/mL) at 37 °C. The
liquid dispersion obtained was purified by size exclusion
chromatography (SEC), using PD-10 columns packed with
Sephadex G-25 medium (GE Healthcare Life Sciences) and
hydrated with water.46 A subsequent filtration through 0.4
µm and 0.2 µm cellulose acetate filters (Fisher Scientific)
yielded the final dispersion of the fenretinide–lenalidomide-
loaded nanomicelles (FLnMs) suitable for in-vivo use.
Nanomicelles without drugs (nMs) or containing fenreti-
nide alone (FnMs) were prepared by the same procedure.
Differential Scanning Calorimetry (DSC)
Thermograms of pure drugs and semisolid mixtures con-
taining the drugs were carried out using Mettler equipment
(Greifensee, Switzerland: FP 80HT control unit, FP 85TA
cell furnace, and FP 89 control software). Samples of
about 10 mg were weighed and analyzed in the range of
20−250 °C, at a heating rate of 10 °C min−1.
Drug Content in the Nanomicelles
In order to evaluate their drug content, the nanomicelle dis-
persions were diluted (1:3 v:v) with an ethanol:water (1:1, v:
v) mixture and analyzed by UV spectroscopy (Shimadzu
UV-1601) at 360 nm for fenretinide and 250 nm for lenali-
domide, in comparison with the empty nanomicelles. The
concentrations obtained represented the drugs encapsulated
in the nanomicelles and free in the aqueous phase. Therefore,
to obtain the concentrations of free drugs, the nanomicelle
dispersions were centrifuged in a 3.5 mL Ultra 5 KDa filter
(MerckMillipore) at 4000 x g for 30 min, and the ultrafiltrate
was spectrophotometrically analyzed for drug content, after
dilution 1:3 with an ethanol:water (1:1, v:v) mixture. The
difference between the whole drug concentration in the
nanomicelle suspension and in the ultrafiltrate provided the
concentration of the encapsulated drugs. The drug loading
was obtained as the ratio between the concentration (w:v) of
the encapsulated drug and the concentration (w:v) of the
nanomicelle dispersion. The encapsulation efficiency as the
ratio between the concentration (w:v) of the encapsulated
drug and the whole drug concentration (w:v) obtained by
spectrophotometric evaluation of the liquid dispersion before
purification by SEC.
Stability of the Nanomicelles Towards
Drug Leakage
The stability of the nanomicelles was measured by dialysis
at 37 °C. The nanomicelle dispersions were diluted 1:10
(v:v) with PBS (pH 7.4) containing 25% human plasma
and placed in a dialysis bag (Mw cutoff 5KD) (Fisher
Scientific) immersed in a receiving compartment contain-
ing PBS (pH 7.4) and n-octanol 5% (v:v). N-octanol was
added to serve as a drug-extractive phase simulating the
presence of cell membranes in vivo.47 Spectrophotometric
analysis in the releasing phase was made at increasing
time intervals, as described above.
Dynamic Light Scattering (DLS)
Characterization
Particle size, polydispersity and zeta potential were mea-
sured at 37 °C on the nanomicelle dispersions diluted 1:10
with water (Malvern Instruments, Worcestershire, UK).
A minimum of 12 measurements per sample were made.
Results were the combination of three 10 min runs for
a total accumulation correlation function time of 30 mins.
The results were volume-weighted.
Confocal Laser-Scanning Fluorescence
Microscopy (CLSFM)
Specimens were analyzed using a Nikon C1s confocal laser-
scanning microscope, equipped with a Nikon PlanApo 60,
1.4-NA oil immersion lens. Excitation light for fenretinide
was obtained by an Argon Ion Laser (405 nm), and emission
was recorded at 650 nm. Optical sections were obtained at
increments of 0.01 µm in the Z-axis and were digitized with
a scanningmode format of 512–512 pixels. Image processing
was performed using ImageJ software.
Cell Lines
SH-SY5Y NB cells stably transfected with NTRK2 (clone
BR6)48 were used for the in-vitro experiments. We tested
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the integrity and authenticity of these cell lines for endo-
toxins, mycoplasma, bacterial and other viral contamina-
tions, and we tested the genetic authenticity of this line by
multiplex PCR techniques. These tests were performed on
an annual basis at the cell center services facility of the
University of Pennsylvania. Cells were grown in RPMI-
1640 medium (Gibco) containing 10% fetal bovine serum
(Cellgro) and maintained in 150 cm3 culture flasks
(Corning) in a humidified atmosphere of 95% air and 5%
CO2. Transfected cells were maintained in media contain-
ing 0.3 mg/mL G418 sulfate (stock solution: 20 mg/mL;
Corning). Cells were harvested using 0.02% tetrasodium
EDTA in phosphate-buffered saline (PBS).
In vitro Experiments
The in vitro effect of FLnMs was evaluated in comparison
with FnMs.We plated 8 x 103 cells per well in 96-well plates
and exposed the cells at FLnM and FnM concentrations
corresponding to 10, 20, 30 μM fenretinide. The free drugs
were also tested at concentrations comparable with those
contained in the nanomicelles. In this case, fenretinide and
lenalidomide were dissolved in ethanol at 1 mM and diluted
with cell medium to the final experimental concentrations.
Viability was evaluated over time using the Incucyte live cell
imaging system (Essen BioScience, MI, USA) and the
image analysis software (S3 Base Software).
Mice
We obtained six-week-old female athymic nude mice from
Jackson Laboratories. Mice were maintained under humid-
ity- and temperature-controlled conditions in a light/dark
cycle that was set at 12 hr intervals. The Institutional
Animal Care and Use Committee (IACUC) of the CHOP
Research Institute approved the mouse xenograft studies
described in this report. The studies were conducted in
accordance with all international, USDA, PHS, AAALAC,
state, and local rules, regulations and ethical principles
regarding the use of animal subjects in research.
Flank Xenograft Experiments
Female athymic nude mice were injected subcutaneously
in the right flank with 1 x 107 TrkB-expressing SY5Y
(BR6) cells suspended in 0.1 mL of Matrigel (Corning,
Tewksbury, MA). Tumors were measured manually 2x/
week in 2 dimensions (mm) using a caliper. The volume
(cm3) was calculated as follows: [(0.523 x L x W2)/1000)]
where L > W. Body weights were obtained 2x/week, and
treatment doses adjusted if there was a >10% change in
body weight. When tumors reached a mean volume of
0.1 cm3, the mice were treated with FLnMs or FnMs by
IV route 3 times/week for 3 weeks at the dose of 30 mg/kg
fenretinide and 17 mg/kg lenalidomide.
Histological Evaluation of Tumors
End point tumors were excised, fixed in 4% paraformaldehyde
and delivered to the CHOP Pathology Core for processing and
histochemical staining. Stains used included hematoxylin and
eosin (H&E), and Ki-67 to assess proliferation.
Evaluation of Fenretinide in Mouse Blood
and Tumors
The concentration of fenretinide was evaluated in blood and
tumors after intravenous administration of FLnMs or FnMs
either as a single administration or as a chronic administra-
tion 3 times/week for 3 weeks. After single administration,
blood and tumor were collected at 4, 24 and 48 hrs after
treatment. For chronic administration, blood and tumor
were collected at 24 hrs after the last treatment. Blood was
obtained via retro-orbital and terminal bleeds and collected
into 2 mL tubes containing sodium heparin (Becton
Dickinson). Tumors were collected after sacrifice. Plasma
was separated from the blood by centrifugation for 15 mins
at 2000 × g at 4°C and stored separately. All samples were
stored in −80°C until analyzed by the CHOP Pharmacology
Core. Total fenretinide levels were analyzed in mouse
plasma and tumor homogenates by UPLC-MS/MS.
Tumors were homogenized using a Biologics Inc. Model
3000 ultrasonic homogenizer. We added 20:80 methanol:
water with 1% formic acid to a known weight of tissue to
obtain a ratio of 4 mL/g sample. Samples were homoge-
nized on ice and frozen until analysis. Standards were pre-
pared in CD-1 mouse plasma containing sodium heparin as
an anticoagulant. A nine-point calibration curve was pre-
pared at different concentrations by spiking a working
stock. Plasma and tumors homogenate samples were
extracted via acetonitrile precipitation in a 96-well format.
Electrospray ionization in the negative ion mode was uti-
lized for the tandem mass spectrometric detection of fenre-
tinide (m/z 391.55→ and m/z 391.55→) using AB Sciex
4000 mass spectrometer. Separation was accomplished uti-
lizing Kinetex PFP (50.4.1 mm id, 2.6 μm) column with
Shimadzu LC 20AD HPLC system with a run time of 4.5
mins. This assay was linear over the range of 1 to 1000 ng/
mL for both fenretinide and fenretinide in mouse plasma.
The matrix factors of the mouse tumor obtained using tissue
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homogenates spiked with 100 ng of fenretinide per mL (n
= 3) against mouse plasma calibration curves were applied
in the drug assay calculations.48
Statistical Analysis
All assays were performed at least in triplicate and
expressed as mean ± SD. Statistical significance was deter-
mined by unpaired Student’s t-test. The data were ana-
lyzed by SPSS 20.0 software. Mouse overall survival was
determined using the Kaplan–Meier method. P values
<0.05 were considered significant.
Results
Characterization of the Nanomicelles
Nanomicelles carrying the fenretinide–lenalidomide com-
bination were prepared by simple dissolution in water of
a semisolid phase containing soy phosphatidylcholine,
glyceryl tributyrate and hydroxypropyl-beta-cyclodextrin
(Figure 1). Confocal laser-scanning fluorescence images,
obtained by exploiting the spontaneous autofluorescence
of fenretinide, showed spherical drug localization inside
FnMs and FLnMs (Figure 2A). Image processing of the
optical sections of the nanomicelles indicated that fenreti-
nide was homogeneously distributed in the inner core of
both FnMs and FLnMs (Figure 2B).
The thermograms of the semisolid phase containing
fenretinide or fenretinide + lenalidomide showed low
melting peaks in the range 120–140 °C, much lower than
the peaks of the pure drugs and at lower temperatures than
the single melting endotherms of the pure drugs (Figure 3).
This suggests that the drugs are mostly solubilized rather
than physically dispersed in the semisolid phase, and the
interactions they establish with the mixture components
unsettle their crystalline state toward an amorphous, dis-
persed state. The mean size of the nanomicelles ranged from
a minimum of 137.7 ± 0.8 for FLnMs to a maximum of
256.5 ± 6.1 for nM, in the range for tumor accumulation by
the EPR effect. Polydispersity was always lower than 0.3,
indicating good dimensional homogeneity. The zeta poten-
tial was negative, with values between - 65.45 and −71.35
mV. (Table 1). The encapsulation efficiency was slightly
higher for fenretinide than lenalidomide: the drug loading
was 7.34 ± 0.4 for fenretinide and 4.25 ± 0.5 for lenalido-
mide (Table 1).
Stability Towards Drug Leakage
The drug leakage from the FLnM micelles was very low:
after 48 h, 17% ± 6.2 fenretinide and 23% ± 8.3 lenalido-
mide were released, indicating nanomicelle stability
towards the release of both drugs in time frames longer
than the circulation time (Figure 4).
In vitro Cytotoxicity of FLnMs
The cytotoxicity of FLnMs was both time- and dose-
dependent (Figure 5A). No significant differences were
observed between FLnMs and FnMs, indicating that the
presence of lenalidomide did not improve the in vitro
cytotoxic activity of fenretinide. Indeed, pure fenretinide
provided a cytotoxic effect comparable to FnMs and
slightly higher than FLnMs (Figure 5B). Pure lenalido-
mide was tested at the same concentrations as fenretinide
(10 μM, 20 μM, 30 μM) that slightly exceeded the lenali-
domide concentration in FLnMs (6.6 μM, 13.2 μM, 19.86
μM) (Figure 5B). However, no cytotoxic effect was
observed with pure lenalidomide, consistent with the lack
of improved cytotoxicity of FLnMs. Empty nanomicelles,
evaluated at the same concentrations as the loaded ones,
had no cytotoxic effect over time (all P<0.05).
In vivo Efficacy of FLnMs
In vivo, FLnMs generated a significant antitumor effect,
higher than FnMs. (Figure 6A). The tumor growth in FLnM-
treated mice was slow and, at the end of administration period,
the mean tumor weights (0.12 ± 0.01 g) were much lower than
from the FnM-treatedmice (0.49 ± 0.03 g) (P <0.05). Also, the
Figure 1 Schematic representation of FLnMs composed of phospholipids and
hydroxypropyl-beta-cyclodextrin in the outer layer and fenretinide + lenalidomide
in the inner core.
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Figure 2 Confocal Laser Scanning image of FLnMs (right) and FnMs (left) showing the presence of autofluorescent fenretinide within micelles (A). 2D representation of 125
depth-resolved slices separated by 10 nm (B). (a) trans-axial slice (XY plane) through FLnMs: (b) XZ cross-section of planes indicated by horizontal line. (c) YZ cross-
sections of planes indicated by vertical line (Bar = 200 nm). (d) trans-axial slice (XY plane) through FnMs: (e) YZ cross-section of planes indicated by vertical line. (f) XZ
cross-sections of planes indicated by horizontal line (Bar = 200 nm).
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survival at the end of treatment was 100% in the FLnM-treated
mice compared to 70% in FnM-treated mice (Figure 6B)
(P< 0.05). The mean body weight of the mice either treated
with FLnMs or FnMs increased over time, as in the controls,
indicating that neither formulation caused significant systemic
side effects (Figure 4C) (P > 0.05).
Evaluation of Fenretinide in Mouse Plasma
and Tumors
The concentration of fenretinide in plasma and tumor tissue
was higher at 4 h than 24 h and 48 h after either FLnM and
FnM administration (Figure 7A and B) (P<0.05). In tumors,
the drug concentrations were always higher than in plasma
at each time point from both FLnMs and FnMs (Figure 7B)
(P<0.05). The drug concentration in tumors was particularly
high 4 h after FLnM administration. No significant differ-
ences were observed in drug plasma levels either after
single and chronic administration of FLnMs and FnMs
(Figure 7C). The chronic administration improved fenreti-
nide concentrations in tumors only with FnM administra-
tion, whereas there was a slight decrease in tumor drug
concentration with chronic vs single FLnM administration
(all P<0.05).
Histologic Evaluation of Tumors
Untreated tumors appeared undifferentiated, with many
compact tumor cells and a high proliferation index
(>30%), as demonstrated by Ki-67 index (Figure 8). The
tumors treated with FnMs were less compact and had
a lower proliferation index (<25%) compared to untreated
tumors (all P<0.05). Cells were large, differentiated and
characterized by a ganglion-like appearance. The tumors
treated with FLnMs exhibited a dramatically different
appearance both grossly and microscopically. They were
Figure 3 Differential scanning calorimetry of the drugs-semisolid phase mixtures: semisolid phase without drugs (SP), mixture with Fenretinide (SP + Fen), mixture with
Fenretinide and Lenalidomide (SP + Fen + Len), pure Fenretinide (Fen), pure Lenalidomide (Len).







Encapsulation Efficiency % Drug Loading % (w:w)
Fenretinide Lenalidomide Fenretinide Lenalidomide
nMs 256.5 ± 6.1 0.291 ± 0.017 −65.45 ± 2.1
FnMs 204.1 ± 2.6 0.258 ± 0.008 −69.17 ± 1.4 91.5 ± 3.2 7.76 ± 0.7
FLnMs 137.7 ± 0.8 0.258 ± 0.006 −71.35 ± 0.6 89.4 ± 5.0 85.1 ± 1.6 7.34 ± 0.4 4.25 ± 0.5
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loosely associated with very few viable cells embedded in
a discontinuous fibrous network with abundant neuropil,
and the proliferation index was very low (<3%) (Figure 8)
(P<0.05).
Discussion
In this study, we used fenretinide in combination with
lenalidomide in novel nanomicelles designed to provide
high encapsulation efficiency and drug loading capacity,
as well as stability to reduce drug leakage, and a size
suitable for tumor extravasation. We prepared the nano-
micelles by a new, single-step method, involving a rapid
dissolution in water of a semisolid amphiphilic phase
consisting of a mixture of lipids, phospholipids, and
hydroxypropyl-beta- cyclodextrin, containing the drugs
in a solubilization state. The self-aggregation in water of
the amphiphilic mixture provided nanomicellar structures
with drug localization in their inner cores as revealed by
confocal scanning microscopy. The complete solubiliza-
tion of the drugs in the semisolid phase, as indicated by
the DSC thermograms, provided high encapsulation effi-
ciency and stability of the nanomicelles to drug leakage.
This was in accordance with the molecular interactions
established by the drugs with the mixture components in
the semisolid phase that persist in the nanomicellar
structures. These characteristics, together with the small
size and low dimensional polydispersity, made the nano-
micelles suitable for drug accumulation in solid tumors
by the EPR effect.
As it is well known, the EPR effect mainly relies on the
ability of nanoparticles injected in the bloodstream to accu-
mulate in solid tumors by extravasation through the capillary
discontinuities generated by the tumor angiogenesis.49
The nanoparticles demonstrate the accumulation of the
loaded drugs at extents that depend on both the nanoparticle
drug loading and their ability to extravasate. As a result, the
EPR effect provides drug accumulation in tumors while
limiting drug distribution to other body compartments.
Accordingly, this increases the therapeutic efficacy and
minimizes the side effects of the administered drugs.50
One of the main nanoparticle characteristics that
improve their efficiency for drug accumulation in tumors
is stability to drug leakage during their circulation time,
allowing them to carry more drug to the tumor.
Additionally, high drug loading and a mean size under
200–250 nm that facilitates extravasation may further
increase the efficiency of drug accumulation.49,50 The
FLnM and FnMs nanomicelles have all these features
and are particularly useful to exploit the EPR effect with
high efficiency.
Indeed, the intravenous administration of FLnMs and
FnMs provided very high fenretinide concentrations in
tumors. The concentrations were higher in tumors than in
plasma either at 4 h, 24 h and 48 h after administration of
both FLnMs and FnMs, indicating an efficient accumula-
tion of the nanomicelles in the NB tumors. Moreover, the
lower mean size of the FLnM nanomicelles might account
for the higher fenretinide concentration in tumors obtained
4 h after administration (Figure 7A and B).
In particular, the administration of 30 mg/kg fenretinide
by FLnMs and FnMs provided 60.8 μg/mL (155.28 μM)
and 52.36 μg/mL (133.72 μM) drug concentrations in
tumors, respectively, at 4 h. These values are much higher
than the concentration range of 1–10 μM that is reported to
be active in vitro in a variety of human cancer cell lines,
including head and neck cancer, non-small cell lung and
small cell lung cancer, breast cancer, ovarian cancer, pros-
tate cancer and pancreatic cancer, as well as neuroblastoma,
Ewing’s family tumors, leukemia, and multiple myeloma.29
No data are reported in the literature about fenretinide
concentrations in tumors, after intravenous administration
of the drug, to compare with FLnMs and FnMs.
A comparison can be made with a nanoformulation of
fenretinide recently developed for oral use.38 In this case,
the fenretinide concentrations in tumor xenografts
obtained 3 h after administration of 100 mg/kg fenretinide
were 3.44 ug/mL (8.78 μM), 1.71 ug/mL (4.36 μM) and
4.98 ug/mL (12.71 μM) in lung cancer, melanoma and
colon cancer xenografts, respectively.
In spite of the differences in tumor types, the comparison
clearly shows the superiority of intravenous over oral
Figure 4 Leakage of fenretinide and lenalidomide from FLnMs in PBS (pH 7.4)
containing 25% human plasma at 37° C. All data are the average of at least three
different experiments ± SD.
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administration for the nanoformulated drug. Indeed, the drug
concentrations in tumors obtained by the intravenous admin-
istration of 30 mg/kg fenretinide were more than tenfold
higher than those obtained with 100 mg/kg fenretinide
administered by oral route. This is in accordance with the
ability of the intravenously injected FLnM and FnM nano-
particles, carrying the loaded drugs, to accumulate in solid
tumors.
Figure 5 Cytotoxic activity of FnMs and FLnMs at increasing fenretinide concentrations in BR6 cells (A). Cytotoxic activity of pure fenretinide and pure lenalidomide at
increasing concentrations in BR6 cells (B). The cells were exposed at the indicated drug doses and cell viability was evaluated by Incucyte after 24, 48 and 72 hrs and
indicated as percentage versus control cells (mean ± SD, n = 8).
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Figure 6 Efficacy of FLnMs and FnMs on BR6 flank xenografts. Cells were implanted subcutaneously in the flank of each mouse. Mice (n=4 per arm) were treated
intravenously via tail vein injections with FLnMs (30 mg/kg fenretinide and 17 mg/kg Lenalidomide) or FnMs (30 mg/kg fenretinide) 3x/week for 3 weeks when tumors
reached a volume of 0.1 cm3. (A) Tumor growth inhibition. (B) Event-free survival curves of mice. (C) Body weight of mice during treatment. (mean ± SD, n = 4).
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Figure 7 Plasma and tumor concentrations of fenretinide in mice treated with FLnMs and FnMs. Mice (n=3 per arm, per time point) were given a single dose of FLnMs
(30 mg/kg fenretinide and 17 mg/kg Lenalidomide) or FnMs (30 mg/kg fenretinide) intravenously via tail vein. After 4, 24 and 48 h fenretinide levels were determined in
plasma (A) and tumors (B). The mice treated with FLnMs (30 mg/kg fenretinide and 17 mg/kg Lenalidomide) or FnMs (30 mg/kg fenretinide) 3x/week for 3 weeks were
sacrificed after 24 h from the last treatment and the concentrations of fenretinide were determined in plasma and tumors (C). (mean ± SD, n = 3).
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In contrast, nanoparticle administration by oral route
does not allow tumor accumulation by the EPR effect
because the oral nanoparticles cannot cross the gastroin-
testinal mucosa in order to reach the circulation.51 Their
role is only to improve the drug solubilization in the
gastrointestinal environment and thus enhance oral drug
bioavailability. This may also increase drug concentration
in tumors as a result of the increased drug-plasma
concentration that affords biodistribution of increased
drug amounts in the different body compartments, includ-
ing the tumor site.38
However, repeated administration of oral nanoformula-
tions is required to achieve high drug levels in tumors that
would be comparable to those achieved by a single admin-
istration of a lower drug dose using intravenously injected
nanoformulations.
Figure 8 Histology of tumor samples. H&E staining of BR6 tumor xenografts: untreated tumors (Control) show packed undifferentiated cells, tumors treated with
fenretinide (FnMs) are less compact and rich in neuropil, treatments with the fenretinide–lenalidomide combination (FLnMs) provide loose cells mostly differentiated with
scarce active cells as demonstrated by the scant nuclear staining. Ki-67 staining show proliferation activity in untreated tumors (Control) with a proliferation index >30%,
a decrease in proliferation in FnMs-treated tumors (proliferation index <25%) and a minimum proliferation activity in FLnMs-treated tumors (proliferation index <3%). (mean
± SD, n = 4).
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Therefore, the high fenretinide concentrations obtained
in NB tumors by FLnMs and FnMs accounted for the
decrease in tumor growth observed with both nanoformu-
lations compared to controls. The effect was evident after
10 days treatment (Figure 6A). The antitumor activity of
FLnMs was higher than FnMs. Indeed, the tumor size after
21 days of treatment in mice receiving the combination
was about sevenfold smaller than those receiving fenreti-
nide alone, and the survival was 100% for the combination
compared to only 70% for the single drug (Figure 6B).
Chronic administration provided fenretinide concentra-
tions in tumors that were higher for FnMs than for
FLnMs (Figure 7C). Nevertheless, the antitumor activity
was much greater for the fenretinide–lenalidomide combi-
nation compared to the nanomicelles with fenretinide
alone. The antiangiogenic effect of lenalidomide is likely
to account for the improved activity of the combination vs
fenretinide alone, as lenalidomide did not show any cyto-
toxicity on the tumor cells in vitro.
It has been reported that the antiangiogenic activity of
lenalidomide in tumors is mainly dependent on inhibition of
Akt-1 phosphorylation in endothelial cells induced by
VEGF.42 This produces inhibitory effects on endothelial cell
survival, association of adhesion junction protein complexes,
migration and vessel formation.43 As a result, lenalidomide not
only represses the formation of new capillary tubes but also
decreases the extension of the established capillary bed in
tumors by inhibition of the endothelial cell survival.
Therefore, the antiangiogenic effect of lenalidomide
may play a double role on the efficacy of the combination
treatment by nanomicelles: 1) it reduces the supply of
nutrients and oxygen to the tumor, and 2) it also decreases
the surface of the tumor capillary endothelium available to
nanomicelle extravasation. This causes a lowered nanomi-
celle extravasation, as demonstrated by the decreased con-
centration of fenretinide in tumors after chronic
administration of FLnMs with respect to FnMs.
However, in spite of the decreased fenretinide concentra-
tion in tumors, FLnM administration provided superior anti-
tumor activity compared to FnM administration. Probably the
antiangiogenic effect of lenalidomide counterbalanced the
decreased fenretinide concentration in tumors. Therefore,
the induction of tumor starvation, due to the reduced supply
of nutrients and oxygen, added to the cytotoxic activity of
fenretinide, provided an overall superior antitumor effect than
was achieved using single fenretinide treatment.
In this study, we used an athymic nude mice model that
allowed us to evaluate the antiangiogenic effect of
lenalidomide on FLnM activity. Further work is in pro-
gress with immunocompetent mouse models to evaluate
the contribution of the immunomodulating effect of lena-
lidomide, reported in the NB microenvironment,44 on the
overall antitumor activity of the fenretinide–lenalidomide
combination in FLnM nanomicelles.
Conclusion
In this study, we demonstrated that the combination of
fenretinide with lenalidomide, administered by a novel
nanomicellar formulation (FLnMs), provided a strong anti-
tumor effect in an NB xenograft model. The nanomicelles
had high encapsulation efficiency, mean sizes in the opti-
mal range for tumor extravasation after intravenous
administration, and the ability to provide high drug con-
centration in tumors. The nanomicelles containing the
fenretinide–lenalidomide combination elicited an antitu-
mor effect that was much higher than the nanomicelles
containing fenretinide alone (FnMs), in spite of the
absence of apparent cytotoxicity of lenalidomide on NB
cells in vitro. This was attributed to the established anti-
angiogenic effect of lenalidomide that, together with the
cytotoxic activity of fenretinide on the tumor cells, pro-
duced an improved overall antitumor effect. Therefore, the
use of the fenretinide–lenalidomide combination in FLnMs
represents a novel therapeutic approach to treat high-risk
tumors, where repeated administration of low-toxicity
agents is required over protracted time-periods to comple-
tely eradicate all residual tumor cells and avoid disease
relapse. Drug accumulation at the tumor site by nanoen-
capsulation is the main requisite for a successful long-term
therapy, as it guarantees high concentration levels of the
active agents in the tumor environment, with minimal
distribution to other organs and tissues throughout the
body. Although FLnMs were tested in a model of NBs in
this study, this novel therapeutic agent would be expected
to be effective in many other solid tumors as well.
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